NicVax is a vaccine that acts by preventing the entry of nicotine into the brain, thus reducing the addictive effects of smoking. In November 2005, the smoking vaccine showed favorable clinical trial results. This week, manufacturer Nabi Biopharmaceuticals said that it has received fast-track status for NicVAX for nicotine addiction and smoking relapse.

"Smoking is the number one preventable cause of death in the western world, yet current smoking cessation therapies do not effectively treat the root cause of the addiction. We believe the vaccine approach inherent to NicVAX will provide clear patient advantages and a strong differentiation from currently marketed and development-stage products."

[Source: WP Herald]